Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiphospholipid syndrome. Proposition for management]

P Sagot1, M Fiks-Sigaud, M Audrain

  • 1Départment de Gynécologie-Obstétrique et Biologie de la Reproduction, CHRU, Nantes.

Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author reply.

BJOG : an international journal of obstetrics and gynaecology·2024
Same author

Which antiseptic to use for a caesarean section? A systematic review and network meta-analysis of randomized controlled trials.

The Journal of hospital infection·2024
Same author

Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats.

The journal of prevention of Alzheimer's disease·2022
Same author

Association between SARS-Cov-2 infection during pregnancy and adverse pregnancy outcomes: A re-analysis of the data reported by Wei et al. (2021).

Infectious diseases now·2022
Same author

A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.

Human reproduction (Oxford, England)·2021
Same author

Review: Why screen for severe combined immunodeficiency disease?

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2020
Same journal

[Neuroprotection for preterm infants with antenatal magnesium sulphate].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Is universal screening for cervical length among singleton pregnancies with no history of preterm birth justified?]

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Lifestyle recommendations for prevention of spontaneous preterm birth in asymptomatic pregnant women].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Guidelines for clinical practice: Prevention of spontaneous preterm birth (excluding preterm premature rupture of membranes) - Introduction].

Journal de gynecologie, obstetrique et biologie de la reproduction·2017
Same journal

[Psychological aspects of abortion].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
Same journal

[Induced abortion: Guidelines for clinical practice - Introduction].

Journal de gynecologie, obstetrique et biologie de la reproduction·2016
See all related articles

Antiphospholipid antibodies increase risks for mothers, including fetal loss and clotting disorders. Screening is recommended only for high-risk patients, with treatment success rates between 53-81%.

Area of Science:

  • Reproductive Immunology
  • Hematology
  • Obstetrics

Context:

  • Antiphospholipid antibodies, specifically antiprothrombinase and anticardiolipin antibodies, are associated with significant obstetric and thrombotic risks in pregnant individuals.
  • These risks include recurrent intrauterine fetal demise and thromboembolic events during pregnancy and postpartum.

Purpose:

  • To define the specific indications for screening antiphospholipid antibodies in obstetric patients.
  • To outline diagnostic criteria and treatment strategies for managing antiphospholipid antibody syndrome (APS) in pregnancy.

Summary:

  • Routine screening for antiphospholipid antibodies is not advised; testing should be reserved for patients with a history of intrauterine fetal death (after 12 weeks gestation) or unexplained venous/arterial thrombosis.

Related Experiment Videos

  • Diagnosis requires strict adherence to established methodologies and criteria.
  • Treatment decisions, including corticosteroids, intravenous immunoglobulin, antiplatelet agents, or heparin, must be individualized based on antibody levels, obstetric history, thrombotic history, and lupus symptomatology.

    • Impact:

    • Establishes guidelines for appropriate antiphospholipid antibody testing, potentially reducing unnecessary screenings.
    • Provides a framework for personalized management of APS in pregnancy, aiming to improve maternal and fetal outcomes.
    • Reports treatment success rates ranging from 53% to 81%, offering valuable prognostic information.